Bionomics Limited (“Bionomics”) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need.

This Expanded Access Policy describes Bionomics’ approach to requests for access to its investigational products outside of clinical trials.

The term expanded access (sometimes referred to as “compassionate use” or “pre-approval access”) is generally used to describe treatment with an investigational product (i.e. a product that has not yet been approved by the U.S. Food and Drug Administration or any other regulatory authority) for a patient with a serious or immediately life-threatening illness in circumstances where there are no comparable or satisfactory alternative treatments available and the patient is ineligible or unable to participate in a clinical trial.

Bionomics does not offer an expanded access program for its investigational products. Bionomics believes that continuing to develop its investigational products within controlled clinical trials is the most appropriate path forward to generate the safety and efficacy data needed for evaluation by regulatory authorities in order to obtain regulatory approval and subsequently, provide widespread access to these products.

Bionomics may revise this Expanded Access Policy at any time.

For questions regarding Bionomics’ Expanded Access Policy, please contact info@bionomics.com.au.

To learn more about Bionomics’ ongoing clinical trials, please refer to www.clinicaltrials.gov for additional details.